Immunome Inc. (IMNM)
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IMNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.25B
- EPS (TTM)
- -$2.52
- Dividend yield
- None
- 52-week range
- 13.49 – 30.06
- Day range
- 18.94 – 19.56
- Volume / Avg
- 1.16M / 1.21M
- Beta
- —
- Shares outstanding
- 118.00M
- Next earnings
- Nov 5, 2026
52-week range
IMNM stock today
Immunome (IMNM) closed at $19.10 on Oct 7, down 1.11% (-$0.215), versus the S&P 500's 0.22% decline. Shares are 36.5% below their 52-week high of $30.06, set on Aug 19, 2026 and 41.5% above the 52-week low of $13.49, in the middle of the past year's range. IMNM is down 11.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 38.2%.
Immunome has posted a net loss over the last twelve months (EPS of -$2.52), so its P/E ratio is not meaningful. Immunome's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunome
Company profileImmunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Clay B. Siegall Ph.D.
- Headquarters
- Bothell, WA
- Employees
- 247
- IPO year
- 2020
- Website
- immunome.com
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$35.20+84.34%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.65
Immunome peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs IMNM |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs IMNM |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs IMNM |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs IMNM |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs IMNM |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs IMNM |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs IMNM |
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs IMNM |
Indexes, lists and sector
Immunome stock FAQ
What is Immunome's stock price today?
IMNM last traded at $19.10 as of Oct 7, 4:00 PM EDT, down 1.11% on the day. Prices are delayed at least 15 minutes.
When is Immunome's next earnings date?
Immunome is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.65.
Who is Immunome's CEO?
Dr. Clay B. Siegall Ph.D. is the chief executive officer of Immunome Inc., which has about 247 employees.
What is the IMNM 52-week high?
The 52-week high for IMNM is $30.06 and the 52-week low is $13.49. The stock is currently 36.5% below its high.